(Q45402744)

English

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis

scientific article published in March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

0 references

type 2 diabetes

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

Wilma Erhardt

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Klas Bergenheim

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Isabelle Duprat-Lomon

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Phil McEwan

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

189-202

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK.

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster).

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care.

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Long-term disease-related costs 4 years after stroke or TIA in Germany

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Costs of managing severe hypoglycaemia in three European countries

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Saxagliptin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study

1 reference

https://api.crossref.org/works/10.2165%2F11597060-000000000-00000

21 January 2018

Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin monotherapy for type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of overweight and obesity among adults with diagnosed diabetes--United States, 1988-1994 and 1999-2002.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22292415

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11597060-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45402744&oldid=2076631011"